Loading...
XSTO
BINV
Market cap202mUSD
Dec 05, Last price  
28.85SEK
1D
-0.69%
1Q
1.23%
Jan 2017
-61.64%
IPO
-97.01%
Name

BioInvent International AB

Chart & Performance

D1W1MN
XSTO:BINV chart
P/E
—
P/S
42.48
EPS
—
Div Yield, %
—
Shrs. gr., 5y
28.94%
Rev. gr., 5y
-13.77%
Revenues
45m
-37.47%
28,198,00050,829,000143,437,000252,138,00080,659,00082,866,000124,649,00042,946,00081,713,00046,932,00015,925,00071,284,00045,014,00038,548,00093,740,000147,372,00019,384,000326,126,00071,461,00044,686,000
Net income
-429m
L+29.99%
-139,862,000-108,833,000-16,093,00016,251,000-176,661,000-128,400,000-67,053,000-187,845,000-18,039,000-53,985,000-90,681,000-62,587,000-100,528,000-123,163,000-139,115,000-76,669,000-278,961,000-34,085,000-330,304,000-429,375,000
CFO
-380m
L+11.35%
-105,479,000-101,228,00012,627,00043,726,000-127,143,000-117,700,000-55,454,000-170,381,000-54,652,000-76,028,000-72,573,000-72,049,000-75,876,000-141,394,000-125,427,000-62,622,000-245,843,000-41,227,000-341,691,000-380,469,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
URL
https://www.bioinvent.com/
IPO date
Jun 12, 2001
Employees
103
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT